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Life-threatening critical congenital heart defects (CCHD), which require intervention in the first few 
weeks of life, occur in about 2 per 1000 livebirths and are an important cause of neonatal mortality 
and morbidity.1-3 Surgical and catheter interventions now provide excellent results for most CCHD 
but timely detection is essential for optimal outcomes.3 Current newborn screening strategies, such 
as antenatal ultrasound and postnatal examination, fail to detect up to one third of infants with 
CCHD before discharge from the place of birth and many of these will either collapse or die prior to 
diagnosis.1-3  
Pulse oximetry screening (POS) has been shown to improve early detection of babies with CCHD by 
identifying those with low oxygen saturations.1-7 POS is simple, quick and painless with a consistent 
test accuracy which increases detection of CCHD.1-3 In addition POS has been shown to be cost-
effective and acceptable to both staff and parents for screening.3  
 
In the USA, POS for CCHD was added to the recommended uniform screening panel in 2011.8 In 
Europe, POS has been adopted by an increasing number of hospitals and pilot studies are currently 
underway in several countries;9 but to-date, only a few (including Poland, Ireland and Switzerland) 
have issued national guidelines recommending universal screening.2  
 
In order to implement strategies to address these gaps, neonatologists, experts in CCHD screening 
and representatives from major European scientific paediatric societies came together to create this 
European recommendation. Full details of the membership and methodology leading to this 
consensus statement can be found at http:// 
 
POS is based on the concept that the majority of babies with CCHD have lower oxygen saturations 
and this was first described over 20 years ago. However, initial small studies were too imprecise to 
establish test accuracy.1-3  
 
Between 2008 and 2014 several large well designed studies, mainly from Europe3-5 but also from 
China,6 consistently demonstrated that POS was a highly specific, moderately sensitive test which 
met the criteria for universal screening. 
 
All studies showed that addition of POS (with new generation ‘motion tolerant’ software) to existing 
screening methods (i.e. antenatal ultrasound and newborn examination) increased the overall 
detection rate to between 90 and 96% irrespective of the detection rates of the other screening 
methods.2,7  Most studies also reported that important non-cardiac conditions, such as respiratory 
and infective disorders and pulmonary hypertension, were also identified as well as the target 
conditions which may be an important additional benefit of POS.4,5,7,10  
 
There is some heterogeneity of screening algorithms adopted in the published studies.4-7, 10,11 These 
differences can be broadly categorised as follows: i) timing of initial screening; ii) use of single or 
dual sites for measuring saturations (post-ductal only or pre and post-ductal); iii) cut-off saturation 
values for a positive test. A full review of the evidence considered by the group can be found at 
http:// 
 
Earlier screening (i.e. within 24 hours of birth) is associated with a higher false positive (FP) rate than 
screening after 24 hours.2,7,11 However, up to 50% of babies with CCHD may present with symptoms 
(including cardiovascular collapse) before 24 hours of age; the same may be true for the non-cardiac 
conditions identified by POS.2 In addition, many countries discharge mother and baby from hospital 
before 24 hours making later screening impracticable.2 The group gave careful consideration to the 
concept of achieving a timely diagnosis even if this was at the expense of a slightly higher false 
positive rate.11 Full details can be found at http:// 
  
When evaluating different screening algorithms it is important to consider sensitivity, specificity, FP 
and false negative rate. It is also vital that screening results in timely diagnosis – i.e. before 
presentation with acute collapse.11 Most PO screening studies report high specificities of >99% and 
FP rates <1% which means that most healthy babies will test negative; however when considering 
national screening programmes a higher FP rate may involve a considerable number of babies.7,11 
This requires careful consideration in order to achieve a balance, both in clinical and economic 
terms, between test sensitivity and FPs. The issue of detection of non-cardiac diagnoses makes this 
more complex although this is generally seen as a potential advantage to screening by clinicians.10,11  
 
In order for a screening test to work in practice it has to be acceptable to the group agreeing to the 
screening (in this case the parents of babies) and to the clinical staff who have to perform the test 
and manage the consequences of the result. The large numbers of babies recruited into studies 
suggests this is acceptable, but a formal assessment of acceptability to parents and staff was 
undertaken as part of the UK PulseOx study.3,5 In addition to assessing acceptability, the anxiety 
created by the test - particularly in mothers of FP babies - was reported.3 Satisfaction with, and 
perceptions of, the test and anxiety and depression following screening were quantified using 
validated questionnaires on samples of mothers whose babies were true positive, FP and true 
negative. All participants were predominantly satisfied with screening and there was no significant 
difference in anxiety in mothers of FPs compared with true negatives.3 Staff perceptions of testing 
were also assessed by focus groups and questionnaires and POS was widely regarded as worthwhile 
and effective across all staff groups.3  
 
Almost all the previous studies screened babies in well baby nurseries in a hospital setting.1 
Consideration of screening in other settings such as babies born out of hospital and those admitted 
to NICU is also important.1   
 
With regard to PO screening, homebirths are different from hospital births as the midwife usually 
leaves the mother and baby after 2 hours. This means screening would either have to be performed 
very early or delayed until the following day. Studies from the Netherlands and the UK both 
demonstrate that screening at 2 hours in homebirths is feasible and although the test positive rate is 
slightly higher, it was reported as clinically acceptable.1  
 
The situation in the NICU is different; babies are usually admitted because they are unwell and/or 
premature and this may affect oxygen saturations. Additionally, NICU babies usually undergo 
continuously PO monitoring. The majority of published screening studies excluded babies admitted 
to the NICU for these reasons; however if national screening programmes are to include all babies 
then it is important to consider whom, how and when to screen. The best approach has yet to be 
determined.  
 
In all published studies, babies who tested positive had a diagnostic echocardiogram to establish any 
CHD and to define test accuracy. This has led to the assumption that during routine screening all test 
positives need an urgent echocardiogram. This is not unreasonable as the consequences of missing a 
CCHD are potentially disastrous. However, it is clear from many reports that the majority of false 
positives (FPs) have an alternative non-cardiac condition determining the test positivity i.e. a 
secondary condition that requires medical attention and prompt management.10,11 As a significant 
proportion of these FPs have a respiratory or infective problem, it may often be that the correct 
diagnosis is made following blood tests or radiographs prior to performing echocardiography and 
echocardiography may be limited to those babies in whom the diagnosis is unclear.10,11  
 
 
The recommendations of our international workgroup which included clinicians from 11 countries, 
CCHD POS experts and senior representatives of major European Paediatric, Neonatal and Perinatal 
Scientific Societies (EAPM, ESPR, EPA-UNEPSA, and UENPS [see below for details]) are shown in Figure 1.  
 
We have tried to create common, shared, reasonable scientific recommendations for using POS for 
early detection of CCHD in Europe. We believe that we have created an evidence-based, and 
importantly, flexible framework for adoption, implementation and standardisation of CCHD 
screening with PO practices across Europe. These recommendations should be considered at a 
national level across Europe, providing an additional tool better to identify these potentially life-
threatening conditions. 
 
Societies represented: European Association of Perinatal Medicine (EAPM) – Umberto Simeoni (President) and Luc J.I. Zimmermann 
(council member) 
European Society for Pediatric Research (ESPR) – Luc J.I. Zimmermann (President) and Daniele De Luca (Council member) 
European Pediatric Association – Union of European Pediatric Societies (EPA-UNEPSA)– Julije Mestrovic (Vice-President) 
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Figure 1. Recommendations of the European pulse oximetry screening workgroup 
 
1. Pulse oximetry screening should be recommended for all European countries.  
2. Pulse oximetry screening should be performed using new generation equipment that is 
motion tolerant.  
3. Screening should occur after 6 hours of life or before discharge (preferably before 24 
hours of life) from the birthing centre.  
4. Screening should be performed in two extremities; the right hand and either foot.  
5. Each European country should consider pros and cons of the Nordic and UK protocols and 
adopt which best suits their population.  
 
 
 
